Grommes et al [42] reported that pulsatile erlotinob at approximately 1500 mg per week was safe and had activity in patients with CNS diseases from EGFR mutant NSCLC even when systemic resistance had developed and been confirmed. This evidence concerns the gene EGFR and non-small cell lung carcinoma.